K
K M Brown
Publications - 6
Citations - 769
K M Brown is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications receiving 764 citations.
Papers
More filters
Assessment of the risk of deficiency in populations and options for its control
TL;DR: This chapter discusses dietary sources of zinc and factors affecting the proportion of zinc available for absorption in the diet, as well as causes of zinc deficiency and groups at high risk.
Journal ArticleDOI
Preparing Future Medicine Physicians to Care for Cancer Survivors: Project ECHO® in a Novel Internal Medicine and Family Medicine Residency Curriculum
Youngjee Choi,Alaina Chodoff,K M Brown,Luis A. Murillo,Jonathan Nesfeder,Marielle T Bugayong,Kimberly S. Peairs +6 more
TL;DR: The Project ECHO curriculum as discussed by the authors is an interactive model of tele-education through Zoom video conferencing, to connect trainees with specialists to teach medicine residents a structured approach to cancer survivorship care.
Journal ArticleDOI
In persons at intermediate risk for CVD, polypills reduce a composite of CV events at 5 y
K M Brown,Anthony J. Donato +1 more
TL;DR: Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Journal ArticleDOI
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin
K M Brown,Anthony J. Donato +1 more
TL;DR: Nathan DM, Lachin JM, Balasubramanyam A, et al. as discussed by the authors proposed a method to reduce glycemia reduction in type 2 diabetes-glycemic outcomes.
Journal ArticleDOI
In hypertension, a quadpill containing quarter doses of 4 BP drugs reduced BP at 12 wk vs. standard-dose monotherapy
K M Brown,Anthony A. Donato MD +1 more
TL;DR: Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension is compared in a phase 3, randomised, double-blind, active-controlled trial.